Premier Alternatives

Innovacell (TKS: 504A)

Tokyo, Japan · Publicly Held

Innovacell Inc is engaged in the development, manufacturing, and sale of regenerative medicine products for the treatment of conditions including fecal and urinary incontinence. Innovacell (TKS: 504A) is based in Tokyo, Japan. It is now publicly traded; this page covers its private-market history, where its last recorded valuation was $364 million (Feb 2026). It has raised $193 million.

Last price · $/share
—
Implied valuation
$364.2M
Total raised
$193.4M
Last round
—

Innovacell (TKS: 504A) key facts

  • Innovacell Inc is engaged in the development, manufacturing, and sale of regenerative medicine products for the treatment of conditions including fecal and urinary incontinence.
  • Innovacell (TKS: 504A)’s last known valuation is $364.2M (Feb 2026).
  • It has raised $193.4M; the latest was IPO ($91.6M) in Feb 2026.
  • Notable investors include SBI Investment, UntroD, HiJoJo Partners, Happiness Capital, Felicity Global Capital — 26 tracked in total.
  • Status: Publicly Held.
Free account
More of Innovacell (TKS: 504A) with a free account
  • ·The complete investor list: 26 names
  • ·Watch Innovacell (TKS: 504A): the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Innovacell (TKS: 504A) funding rounds

No rounds on record

No funding rounds for Innovacell (TKS: 504A) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

Innovacell (TKS: 504A) valuation

Innovacell (TKS: 504A) is now publicly traded; this page covers its private-market history, where its last recorded valuation was $364 million (Feb 2026). Secondary trades, fund marks and rounds below are the private-market record; the listed share price is not tracked here.

Innovacell (TKS: 504A) investors

26 investors are on record for Innovacell (TKS: 504A), including SBI Investment, UntroD, HiJoJo Partners and Happiness Capital.

About Innovacell (TKS: 504A)

Innovacell Inc is engaged in the development, manufacturing, and sale of regenerative medicine products for the treatment of conditions including fecal and urinary incontinence. Its activities include researching potential therapeutic candidates, developing formulations, and commercializing products in the markets. The company is working on the development and commercialization of the following three cell therapy pipelines targeting incontinence (fecal and urinary incontinence): ICEF15, ICEF16, and ICES13.

Sector
Healthcare
HQ
Tokyo, Japan
Employees
48
Ownership
Publicly Held

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.

Valuation on record
$364.2M

Innovacell (TKS: 504A)’s last known valuation, Feb 2026. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.